Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Detailed Analysis of Current Industry Figures with Forecasts Growth

SDKI Inc. published a new report on "Ornithine Transcarbamylase (OTC) Deficiency Treatment Market-Global Forecast 2022-2031". This study includes the statistical and analytical approaches needed to grow the ornithine transcarbamylase (OTC) deficiency treatment market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-111239

The ornithine transcarbamirase (OTC) deficiency treatment market is estimated to reach approximately US $ 882 million by 2031, from a market value of approximately US $ 645 million in 2022, 4 during the 2022-2031 forecast period. It is expected to grow at a% CAGR.

Ornithine transcarbamylase deficiency is a very common urea cycle disorder. It is a rare X-linked hereditary disease. It is characterized by a partial or complete deficiency of the enzyme ornithine transcarbamylase (OTC). OTC is one of the six enzymes responsible for breaking down and removing nitrogen in the body, a process known as the urea cycle. OTC deficiency is a hereditary disease. This is an abnormal gene on the X chromosome that appears primarily in men. Both men and women can develop symptoms of OTC deficiency in childhood. Females with a defective gene on one of the X chromosomes are carriers of this disorder.

Increasing prevalence of OTC deficiency and the development of new therapies for the treatment of OTC deficiency are key factors driving the growth of the global ornithine transcarbamylase (OTC) deficiency treatment market. According to Orphanet, the estimated prevalence of ornithine transcarbamylase deficiency ranges from 1 / 56,500 to 1 / 113,000 birth rates worldwide. Favorable reimbursement scenarios and patient support programs offered by various international and regional organizations are also contributing to the growth of the ornithine transcarbamylase (OTC) deficiency treatment market. The bitterness and stink of the product can affect patient compliance. Therefore, research and development is underway to develop new formulations of this drug to overcome these serious problems.

Sample URL of the report
https://www.sdki.jp/sample-request-111239

Ornithine transcarbamylase (OTC) deficiency treatment market segment

The ornithine transcarbamirase (OTC) deficiency treatment market is by product (buphenyl, rabich, ammonul, dietary supplements, etc.), by route of administration (oral and intravenous), by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies). ), And divided by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Regional overview

ornithine transcarbamylase (OTC) deficiency treatment market The ornithine transcarbamylase (OTC) deficiency treatment market is further subdivided based on the region, and the market growth of each country is evaluated. These include North America (US, Canada, and other North America), Europe (Germany, France, Italy, Spain, UK, and other Europe), Asia Pacific (China, Japan, India, Australia, Singapore, and others). Asia Pacific) and other regions.

The North American region dominates the global ornithine transcarbamylase (OTC) deficiency treatment market in 2019, and this trend is projected to continue for the duration of the forecast. The availability of well-defined reimbursement policies from public and private health insurance companies is a key driver of the growth of the ornithine transcarbamylase (OTC) deficiency treatment market in the region. It helps patients have easy access to diagnostics and extensive R & D activities. In addition, an increasing number of reported ornithine transcarbamylase (OTC) deficiencies, the presence of large companies, various clinical studies in the region on urea cycle disorders, and a better screening approach for rare diseases also contributed to the growth of the market in the region. doing.

Key Players in the Ornithine Transcarbamylase (OTC) Deficiency Treatment Market

The key players in the ornithine transcarbamylase (OTC) deficiency treatment market are Abbott, Nutricia (Danone Group), Mead Johnson (Reckitt Benckiser) and Horizon Therapeutics. These include plc, Nestlé, Bausch Health Companies, Inc., Ultragenyx Pharmaceutical Inc., Arcturus Therapeutics, Inc. and Acer Therapeutics. The study includes a detailed competitive analysis of these leading companies in the ornithine transcarbamylase (OTC) deficiency treatment market, corporate profiles, recent developments, and key market strategies.

Details of the survey report
https://www.sdki.jp/press-details/ornithine-transcarbamylase-otc-deficiency-treatment-market/683

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

This release was published on openPR.